In The News
Abingworth, Clarus Fuel SFJ Pharma With $45MBrian Gormley
VenureWire Lifescience
March 16, 2009
March 16, 2009
SFJ Raises $45 Million
BioCentury Extra
March 16, 2009
SFJ (Pleasanton, Calif.) raised $45 million in a series A round co-led by Abingworth Management and Clarus Ventures. SFJ is planning to in-license drugs already approved in or in late-stage development in Europe and the U.S. to develop and market in Japan.
Mission
SFJ Pharmaceuticals, Inc.'s mission is to bring new and innovative drugs to Japan, from the U.S., Europe and other global markets, to ensure Japanese physicians and patients have access to more life saving and life enhancing drugs to address their therapeutic needs.Target Market
SFJ Pharmaceuticals, Inc. is solely focused on developing and obtaining regulatory approval for drugs for the Japanese market.SFJ Pharmaceuticals, Inc. is positioned to develop prescription drugs in any and all therapeutic areas, where there is a medical and market need in Japan.